|
|
|
Volumn 5, Issue 3, 2003, Pages 326-330
|
|
Technology evaluation: PK1, pfizer/cancer research UK
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIEMETIC AGENT;
ANTINEOPLASTIC AGENT;
DOXORUBICIN;
DOXORUBICIN DERIVATIVE;
DRUG METABOLITE;
FCE 28068;
N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER;
PK 1;
ANEMIA;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BLOOD TOXICITY;
BREAST CANCER;
CANCER RESEARCH;
CARDIOTOXICITY;
CLINICAL TRIAL;
COLON CANCER;
CONGESTIVE HEART FAILURE;
DOSE RESPONSE;
DRUG CLEARANCE;
DRUG CONJUGATION;
DRUG DESIGN;
DRUG EFFICACY;
DRUG METABOLISM;
DRUG SENSITIVITY;
DRUG SYNTHESIS;
FEBRILE NEUTROPENIA;
HEART ARRHYTHMIA;
HUMAN;
IMMUNOGENICITY;
LICENSING;
LIVER TOXICITY;
LUNG NON SMALL CELL CANCER;
MOUSE;
MUCOSA INFLAMMATION;
NAUSEA AND VOMITING;
NEUROTOXICITY;
NONHUMAN;
PATENT;
PLASMA HALF LIFE;
RAT;
SINGLE DRUG DOSE;
STRUCTURE ACTIVITY RELATION;
THROMBOCYTOPENIA;
UNITED KINGDOM;
ACRYLAMIDES;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
DOXORUBICIN;
DRUG DELIVERY SYSTEMS;
GLUCOSE;
HUMANS;
NEOPLASMS;
PRODRUGS;
|
|
EID: 0141613679
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (27)
|
|
References (0)
|
